These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 11809865)

  • 1. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
    Amacker M; Hübscher U
    J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme.
    Tasara T; Amacker M; Hübscher U
    Biochemistry; 1999 Feb; 38(5):1633-42. PubMed ID: 9931031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Rattanabunyong S; Choengpanya K; Suwattanasophon C; Kiriwan D; Wolschann P; Lamtha T; Shaikh AR; Rattanasrisomporn J; Choowongkomon K
    J Vet Sci; 2023 Sep; 24(5):e67. PubMed ID: 38031646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
    Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
    J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
    Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
    J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
    Pelemans H; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
    J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feline immunodeficiency virus reverse transcriptase: expression, functional characterization, and reconstitution of the 66- and 51-kilodalton subunits.
    Amacker M; Hottiger M; Hübscher U
    J Virol; 1995 Oct; 69(10):6273-9. PubMed ID: 7545246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.
    Menéndez-Arias L; Abraha A; Quiñones-Mateu ME; Mas A; Camarasa MJ; Arts EJ
    J Biol Chem; 2001 Jul; 276(29):27470-9. PubMed ID: 11353775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological Mg
    Achuthan V; Singh K; DeStefano JJ
    Biochemistry; 2017 Jan; 56(1):33-46. PubMed ID: 27936595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
    Galilee M; Alian A
    PLoS Pathog; 2018 Jan; 14(1):e1006849. PubMed ID: 29364950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.